About Index Trending news
Resverlogix Corp.

Resverlogix Corp.

Resverlogix Corp.

RVX-208 is a first-in-class, selective BET bromodomain inhibitor treating patients with cardiovascular disease, diabetes mellitus, and other serious diseases.


Contributors to this profile

Alexa global traffic share

Twitter followers

21 Jun 2017
Post-IPO equity
Eastern Capital, Shenzhen Hepalink Pharmaceutical Co Ltd

Eastern, Hepalink invest in Resverlogix's $10 mln offering

PE Hub
03 Jul 2014
Post-IPO debt
11 Jun 2014
Post-IPO equity
29 Mar 2010
Venture capital